
Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MCRB · as of Jun 9, 2026
Key Statistics
Explore Seres Therapeutics, Inc. Data
mcrb stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 18 · Buy rate: 61.1%
The MCRB analyst consensus is Buy, based on ratings from 18 Wall Street analysts over the past 3 months. The average 12-month price target is $1.25, representing -80.10% downside from the current price of $6.28.
Competitors & Peers
mcrb competitorsStock Performance
Full HistoryAbout Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship thera…
what is seres therapeutics, inc. · mcrb stock overview · seres therapeutics, inc. company profile · who is seres therapeutics, inc. ceo · mcrb NASDAQ · seres therapeutics, inc. headquarters · seres therapeutics, inc. business segments
About Stock Overview & Key Data
Seres Therapeutics, Inc. (MCRB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 26, 2015. As of the latest trading session, MCRB stock price is $6.28, with a market capitalization of $60.8M. The stock has returned -22.94% over the past 12 months and -57.80% year-to-date.
According to 18 Wall Street analysts, the consensus rating for Seres Therapeutics, Inc. stock is Buy, with an average 12-month price target of $1.25. In fiscal year 2025, Seres Therapeutics, Inc. reported revenue of $789000.00 and net income of $5.7M. For detailed data — including Seres Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Seres Therapeutics, Inc. (MCRB) stock price is $6.28. The stock is traded on NASDAQ under the ticker symbol MCRB. The 52-week range is $6.01 – $29.98.